Thomas Brott MD

Thomas G. Brott, M.D., is a neurologist at Mayo Clinic Hospital in Jacksonville, Florida, who treats conditions that include: atrial fibrillation, cerebrovascular disease, intracranial hemorrhage, ischemic stroke, and subarachnoid hemorrhage. He performs procedures that entail left atrial appendage closure, transplants, and therapeutic hypothermia. Dr. Brott is passionate about acute stroke therapy, hemostatic markers in acute ischemic stroke, aneurysmal subarachnoid hemorrhage, intracranial hemorrhage, and hypothermia for ischemic brain injury.

Dr. Brott received his medical degree from the University of Chicago, followed by his medical internship at Beth Israel Deaconess Medical Center in Boston, Massachusetts (formerly Beth Israel Hospital). He then completed his neurology residency at the Harvard Longwood Neurology Program in Boston. He has served as chair of the Stroke Council of the American Heart Association, vice-chair of the National Stroke Association, and chair of the Advisory Committee to the Neurological Devices Panel of the FDA. He received the 2013 Clinical Research Prize and the 2017 Research Achievement Award conferred by the American Heart Association. Mayo Clinic honored him with the Distinguished Investigator award in 2014.

Dr. Brott has been the principal designer of the National Institutes of Health Stroke Scale, which is used worldwide as the examination tool for patients with stroke. He and his stroke team performed one of the first studies that identified the potential of tissue plasminogen activator (tPA) as an acute treatment for ischemic stroke. Subsequent studies by Dr. Brott and others led to approval of tPA as a safe and effective acute treatment for stroke by the Food and Drug Administration (FDA).

Dr. Brott's team was the first to characterize the first minutes following onset of spontaneous intracerebral hemorrhage. He has served as principal investigator of multiple NIH-funded CREST trials with medical centers across the U.S. and Canada. Currently, Dr. Brott is the Director and national principal investigator for an international randomized trial called CREST-2 at 143 medical centers in the U.S., Canada, Spain, Israel, and Australia. The trial is funded by the National Institutes of Health (NIH) and compares treatments for severe narrowing of the carotid artery in patients who have not had a stroke or warning signs of stroke due to the narrowing.